SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as investors weigh the stock's turnaround potential and recent cost-cutting measures against ongoing concerns about North American user growth and leadership direction. The community remains deeply divided, with some betting on a breakout driven by AR innovation and improved profitability, while others view the stock as a perennial underperformer waiting for a management overhaul.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility and intense debate among investors as they position themselves for upcoming earnings, with discussion centered on the launch of its new Agentic AI platform, OASYS, and a flurry of strategic partnership news. While bulls cite growing institutional interest and technical potential as signs of a pending breakout, bears continue to express skepticism regarding the company's profitability and reliance on legacy acquisitions.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Investors are actively debating whether SLV is entering a long-term bull market fueled by industrial demand and geopolitical instability, or if it is currently a trap prone to price manipulation and volatility. Community sentiment remains deeply divided, with some traders citing supply deficits and potential short squeezes, while others point to weak price action and ongoing correlation with oil prices as reasons for skepticism.

Flutter Entertainment Plc engages in the business of online betting and gaming. It operates through the following segments: UK and Ireland, Australia, International, and US. The UK and Ireland segment includes the operations of Sky Betting and Gaming, Paddy Power, Betfair, and tombola. The Australia segment focuses on sports betting services provided to Australian customers online. The International segment relates to poker, casino, rummy, lottery, and sports betting. The US segment includes sports betting, daily fantasy sports, and gaming services. The company was founded in 1988 and is headquartered in New York, NY.

Flutter Entertainment Plc

Flutter Entertainment is experiencing heightened volatility and bearish sentiment as the company navigates a leadership transition at its FanDuel division following the departure of its CEO. Investors are closely monitoring how the incoming leadership will address intensifying competition from prediction markets and a recent reduction in full-year earnings guidance.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as investors and the 'Open Army' community brace for an upcoming earnings release that many see as a critical test of management's turnaround strategy. Discussions are dominated by speculation over potential short-squeeze activity, the impact of recent housing market data, and high expectations for forward-looking guidance.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is surging as investors react to a strategic partnership with Corning to scale optical fiber production for AI infrastructure, further solidifying its dominant position in the AI hardware ecosystem. The stock is seeing significant bullish sentiment and heavy call option flow, with market participants eagerly rotating into the company ahead of its upcoming earnings report.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is trending following the release of preclinical data showing its ERNA-101 candidate achieved complete tumor clearance in ovarian cancer models. While the community is debating the significance of these animal studies versus the risks of potential future dilution, traders are actively monitoring the stock for momentum and a potential short squeeze due to its low float and high borrow costs.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing heightened scrutiny and bearish sentiment as the community closely monitors regulatory crackdowns on prediction markets and concerns over management's share-selling activity. Traders are particularly focused on upcoming earnings, debating whether the stock's recent volatility represents a structural decline or a setup for a potential rebound.

PENN Entertainment, Inc. engages in the provision of integrated entertainment, sports content, and casino gaming services. It operates through the following business segments: Northeast, South, West, Midwest, Interactive, and Other. The Northeast segment includes Ameristar East Chicago, Hollywood Casino, Hollywood Gaming, Marquee, and Plainridge Park Casino operations. The South segment manages 1st Jackpot Casino, Ameristar Vicksburg, Boomtown, Hollywood Casino Gulf Coast, Hollywood Casino Tunica, L’Auberge, and Margaritaville Resort Casino. The West segment is involved in Ameristar Black Hawk, Cactus Petes and Horseshu, M Resort Spa Casino, and Zia Park Casino operations. The Midwest segment focuses on Ameristar Council Bluffs, Argosy Casino, Hollywood Casino, Prairie State Gaming, and River City Casino operations. The Interactive segment refers to an online gaming portfolio which includes ESPN BET, Hollywood Casino, theScore Bet, and PENN Game Studios. The Other segment consists of stand-alone racing operations, namely Sanford-Orlando Kennel Club, Sam Houston, and Valley Race Park. The company was founded by Peter M. Carlino in 1982 and is headquartered in Wyomissing, PA.

PENN Entertainment Inc

PENN Entertainment Inc.

PENN Entertainment is drawing attention as investors weigh the impact of mixed Q4 earnings and ongoing management pressure, with the community closely tracking whether the current digital strategy and cost-saving initiatives can offset competitive challenges. Shareholders remain divided, balancing optimism over regional casino performance and new board oversight against frustrations regarding long-term stock stagnation and the company's path to profitability in the interactive sector.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is trending following a significant share price decline after an earnings report revealed recession-level demand for appliances and the suspension of its dividend. Investors are actively debating the company's long-term viability, with many focused on whether this represents a bottoming point for a cyclical play or a deeper structural decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incannex Healthcare (NASDAQ:IXHL) Stock Price Up 2.8%  - Here's Why

Incannex Healthcare (NASDAQ:IXHL) Shares Up 2.8% - What's Next...

<ul class="summary-bullets"><li>Incannex stated that its financial position is strong, with about $75 million in cash and no debt on its books.</li><li>The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.</li><li>Incannex is currently undertaking trials of IHX-42X and PSX-001 for the treatment of Obstructive Sleep Apnea and Generalized Anxiety Disorder, respectively.</li></ul>Incannex Healthcare Inc. (IXHL) on Friday announced that it has reactivated its share repurchase program, saying that it has been active over the past two trading days.The company cited a “significant disconnect” between its market capitalization and the underlying financial strength, as well as the progress it has achieved across its clinical programs.Incannex stated that it intends to continue utilizing the share repurchase program “opportunistically.”<a href="https://stocktwits.com/symbol/IXHL">Incannex Healthcare</a> shares gained more than 6% in Friday’s opening trade before paring some of the gains. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Incannex Touts Financial Strength</h2>The company stated that its financial position is strong, with about $75 million in cash and no debt on its books.“We are in a strong financial position to execute on our clinical development strategy while maintaining the flexibility to allocate capital in a disciplined and strategic manner,” said Incannex CEO Joel Latham.Incannex is currently undertaking trials of IHX-42X and PSX-001, its treatments for Obstructive Sleep Apnea (OSA) and Generalized Anxiety Disorder (GAD), respectively.The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.<h2 class="st-heading-2">Incannex’s Obstructive Sleep Apnea Trial</h2>Incannex stated that Phase 2 clinical trials showed that IHX-42X’s lowest dose is the most effective for addressing OSA, reducing the Apnea-Hypopnea Index (AHI) by 51% compared with baseline. Incannex stated that one in four participants reported an 80% reduction in AHI.AHI is a key metric for gauging the severity of OSA, measuring how many apneas (complete breathing pauses) and hypopneas (partial airway blockages) occur per hour of sleep.The company said a global Phase 2/3 trial is currently underway to assess the efficacy and safety of IHL-42X.<h2 class="st-heading-2">Incannex’s Generalized Anxiety Disorder Trial</h2>The company noted that in the Phase 2 clinical trial of PSX-001 for the treatment of Generalized Anxiety Disorder (GAD), 44% of the participants who received the treatment reported a clinically meaningful or at least a 50% reduction in their anxiety scores.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> is down 68% year-to-date and 84% over the past 12 months. AdvisorShares Psychedelics ETF (PSIL) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-gctk-stock-soaring-today/cZ3HcZMRIlU">GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Incannex Reactivates Share Repurchase Program, Cites ‘Significant Disconnect’ Between Its Market Cap And Financial Strength

Incannex Healthcare - The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

IXHL Stock Gains As Incannex Reactivates Share Repurchase Program

Equity

The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

Incannex Healthcare Stock Falls 35% Over Announcement Of IHL-42X Development Plan, Stock Offering

(RTTNews) - Shares of Incannex Healthcare Inc. (IXHL) are falling about 35 percent on Thursday morning trading following the announcement of an enhanced clinical development strategy for IHL-42X, its...

<ul class="summary-bullets"><li>If the warrants are fully exercised for cash, Incannex could receive up to an additional $13 million.</li><li>The company said the funds should support completion of the Phase 2 DReAMzz study for its IHL-42X program.</li><li>Phase 2 RePOSA trial showed that IHL-42X delivered statistically significant improvements, reducing breathing interruptions during sleep, preserved REM sleep, and showed no serious safety concerns.</li></ul>Shares of Incannex Healthcare Inc (IXHL) fell 35% on Thursday, after the company announced the pricing of its $10 million private placement. The company also shared that the Phase 3 development of its oral drug candidate for obstructive sleep apnea is not expected to begin until the second half of 2027.The company plans to issue 2 million shares of common stock, or equivalents, along with warrants to purchase up to another 2 million shares at a combined price of $5.00 per share and accompanying warrant. IHXL shares closed at $5.97 in the previous session.&nbsp;Incannex announced that it has ceased using its at-the-market (ATM) facility and has no plans to use it again.If the warrants are fully exercised for cash, Incannex could receive up to an additional $13 million, bringing total potential proceeds to about $23 million. The company said the funds should support completion of the Phase 2 DReAMzz study for its IHL-42X program, while existing cash will remain available for planned Phase 3 development expected to begin in the second half of 2027.<h2 class="st-heading-2">Incannex’s Plan Ahead</h2>The firm said it has updated the clinical development strategy for its oral drug candidate IHL-42X, to treat obstructive sleep apnea, after positive results from its Phase 2 study. The therapy has also received Fast Track designation from the U.S. Food and Drug Administration.The company intends to run a Phase 2 crossover study, known as DReAMzz, to optimize the drug’s dosage before advancing to a streamlined Phase 3 program. The study aims to improve dosing precision and build stronger clinical data ahead of late-stage development.Results from the Phase 2 RePOSA trial showed that IHL-42X delivered statistically significant improvements. The treatment reduced breathing interruptions during sleep, preserved REM sleep, and showed no serious safety concerns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp selloff, retail sentiment for <a href="https://stocktwits.com/symbol/IXHL">IXHL</a> on Stocktwits turned ‘extremely bullish,’ amid ‘extremely high’ message volumes.One user said that while the financing itself isn’t too negative, management’s communication regarding the delayed Phase 3 trial has been poor.<stembedurl>https://stocktwits.com/pavaaan/message/647327564</stembedurl>Another user said the offering “looks worse than it actually is.”<stembedurl>https://stocktwits.com/SurfyKnagg/message/647333529</stembedurl>Year-to-date, the stock has slumped 66%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IXHL Stock Slump 35% Today?

The company priced its private placement at $5 per share, below its previous closing price of $5.97, and said the proceeds would be used for its Phase 3 treatment for sleep apnea, which is expected to begin in the second half of 2027.

<ul class="summary-bullets"><li>To support compliance, Incannex implemented a 1-for-30 reverse stock split on Feb. 26, reducing the number of outstanding shares from 358 million to about 11.9 million.</li><li>Interest has also been driven by regulatory progress for the company’s sleep apnea drug, which received Fast Track designation from the FDA in December.</li><li>Incannex plans to advance the sleep apnea therapy toward late-stage development this year.</li></ul>Shares of Incannex Healthcare (IXHL) surged to their strongest session in five months on Wednesday as investors looked ahead to potential Nasdaq compliance and upcoming regulatory discussions for the company’s sleep apnea drug.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped over 19% on Wednesday to close at $5.97, marking the company’s third straight session of gains.<h2 class="st-heading-2">Nasdaq Compliance Timeline</h2>Incannex said in October that Nasdaq had granted it a 180-day extension to regain compliance with the exchange’s minimum bid price requirement, giving the company until April 20 to meet the rule. Under Nasdaq guidelines, companies must maintain a closing bid price of at least $1 for at least 10 consecutive trading days to regain compliance.As part of its efforts to regain compliance, Incannex implemented a 1-for-30&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-ixhl-stock-tank-over-today/cZRy4khRIGO">reverse stock split</a> effective Feb. 26, with trading on a split-adjusted basis beginning the following day. The move reduced the company’s outstanding share count from 358 million to 11.9 million shares, while lifting its per-share price.<h2 class="st-heading-2">Regulatory Catalyst For Sleep Apnea Drug</h2>Investor interest has also been supported by regulatory momentum for the company’s lead obstructive sleep apnea therapy, IHL-42X, which received&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/incannex-healthcare-stock-soars-15-after-fda-fast-tracks-obstructive-sleep-apnea-drug/cLIXxacRE1t">Fast Track designation</a> from the U.S. Food and Drug Administration in December.The designation followed positive results from the company’s Phase 2 RePOSA study, which showed the therapy significantly reduced breathing interruptions during sleep, with reductions of up to 83% in some patients, along with positive patient feedback and a favorable safety profile.Fast Track status allows for more frequent meetings with the FDA, eligibility for rolling review of a future drug application, and the possibility of accelerated approval or priority review if the therapy meets relevant criteria. Incannex expects to receive written feedback from the FDA on its Phase 2 data package and clinical development strategy, which will help determine the path toward late-stage clinical development.<h2 class="st-heading-2">Clinical Pipeline Backed By Solid Cash Runway</h2>Incannex has also highlighted a strengthened financial position as it advances its clinical pipeline. In January, the company said it entered 2026 with more than $70 million in cash, providing an operating runway well into 2027.During 2025, the company reported two positive Phase 2 clinical readouts, including results for its sleep apnea program and a separate psilocybin-based therapy for generalized anxiety disorder. Incannex said it plans to advance the sleep apnea program toward later-stage development, while continuing regulatory planning for the anxiety treatment this year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IXHL was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ixhl_ss_png_a8ed2aecde.webp" alt="ixhl ss.png" width="973" height="141"><figcaption>IXHL sentiment and message volume as of March 12 | Source: Stocktwits</figcaption></figure>One user <a href="https://stocktwits.com/Santa_Claus_Trades/message/647252179">said</a> they were continuing to hold their position and planned to add shares ahead of the Nasdaq compliance window, noting the stock often moves higher heading into potential news, including a possible announcement of an end-of-Phase 2 meeting.<stembedurl>https://stocktwits.com/Santa_Claus_Trades/message/647252179</stembedurl>Another user <a href="https://stocktwits.com/Nawaf643/message/647272427">said</a>, “Tomorrow is Day 10 above $1 — compliance locked. The real show may start after that. Be ready… big news could start dropping as soon as tomorrow.”<stembedurl>https://stocktwits.com/Nawaf643/message/647272427</stembedurl>IXHL stock has declined 73% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms

IXHL Stock - Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Investors are watching the company’s Nasdaq compliance timeline after it received a 180-day extension until April 20 to meet the $1 minimum bid rule.

Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 842,808 shares, a drop of...

Incannex Healthcare (NASDAQ:IXHL) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised Incannex Healthcare to a "sell" rating in a report on Saturday...

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - What's Next?

Incannex Healthcare (NASDAQ:IXHL) Stock Price Down 11% - Here's Why...

<ul class="summary-bullets"><li>The reverse split will consolidate every 30 existing shares into one new share.</li><li>The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.</li><li>After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million.</li></ul>Incannex Healthcare Inc. (IXHL) announced on Wednesday that its board of directors has approved a 1-for-30 reverse stock split, which was previously approved by shareholders at a special meeting on May 27, 2025.The reverse split is set to take legal effect at 4:01 p.m. ET on Feb. 26, 2026.<h2 class="st-heading-2">Purpose And Impact Of The Split</h2>Following this adjustment, Incannex Healthcare common shares will begin trading on The Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’.The reverse split will consolidate every 30 existing shares into one new share, aiming to raise the per-share market price. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements and maintain continued listing eligibility.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/IXHL">Incannex stock</a> tumbled over 32% on Wednesday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Share Structure And Equity Adjustments</h2>Incannex said that&nbsp;no fractional shares will be issued, and shareholders entitled to fractional amounts will receive an additional share to round up to a whole unit.&nbsp;After the split, the company’s outstanding shares will decrease from roughly 358.3 million to about 11.94 million, although the total number of authorized shares will remain unchanged. Existing equity awards and stock incentive plans will see proportional adjustments in both share numbers and exercise prices to reflect the split.&nbsp;In January, Incannex said it is entering 2026 with over $70 million in cash, following a $12.5 million private placement financing and the elimination of legacy Series A warrants. The company also authorized a $20 million share repurchase program.IXHL stock has declined by over 87% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-q4-earnings-today-retail-says-pressure-is-worse-this-time/cZRy3JBRIG4">Nvidia Q4 Earnings Today – Retail Says 'Pressure Is Worse This Time’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IXHL Stock Tank Over 32% Today? 

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. The move is intended to help the company comply with Nasdaq’s minimum bid price requirements.

The company’s board approved a 1-for-30 reverse stock split, effective on February 26. 


Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest

Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 21,688,567...

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

IXHL
Incannex Healthcare Limited - ADR

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest IXHL News

IXHLIncannex Healthcare Limited - ADR